Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Enhancing Whole Phage Therapy and Their Derived Antimicrobial Enzymes through Complex Formulation
Stockholm University, Faculty of Science, Department of Molecular Biosciences, The Wenner-Gren Institute.
Stockholm University, Faculty of Science, Department of Molecular Biosciences, The Wenner-Gren Institute.
Stockholm University, Faculty of Science, Department of Molecular Biosciences, The Wenner-Gren Institute.
Number of Authors: 32018 (English)In: Pharmaceuticals, ISSN 1424-8247, E-ISSN 1424-8247, Vol. 11, no 2, article id UNSP 34Article, review/survey (Refereed) Published
Abstract [en]

The resurgence of research into phage biology and therapy is, in part, due to the increasing need for novel agents to treat multidrug-resistant infections. Despite a long clinical history in Eastern Europe and initial success within the food industry, commercialized phage products have yet to enter other sectors. This relative lack of success is, in part, due to the inherent biological limitations of whole phages. These include (but are not limited to) reaching target sites at sufficiently high concentrations to establish an infection which produces enough progeny phages to reduce the bacterial population in a clinically meaningful manner and the limited host range of some phages. Conversely, parallels can be drawn between antimicrobial enzymes derived from phages and conventional antibiotics. In the current article the biological limitations of whole phage-based therapeutics and their derived antimicrobial enzymes will be discussed. In addition, the ability of more complex formulations to address these issues, in the context of medical and non-medical applications, will also be included.

Place, publisher, year, edition, pages
2018. Vol. 11, no 2, article id UNSP 34
Keywords [en]
bacteriophage, pharmacology, synergy, formulation, combination therapy, product development
National Category
Biological Sciences Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:su:diva-161226DOI: 10.3390/ph11020034ISI: 000445152300004PubMedID: 29671806OAI: oai:DiVA.org:su-161226DiVA, id: diva2:1257159
Available from: 2018-10-19 Created: 2018-10-19 Last updated: 2018-10-19Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Cooper, Callum J.Koonjan, ShazeedaNilsson, Anders S.
By organisation
Department of Molecular Biosciences, The Wenner-Gren Institute
In the same journal
Pharmaceuticals
Biological SciencesPharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 22 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf